All In Biotech

Drug Trial Radar · NCT03895801

Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.

A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)

Last checked: Nov 19, 2026Latest source record: Aug 25, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

57

Actual

Start

Apr 3, 2019

Primary completion

Apr 14, 2021

Study completion Jun 8, 2021

Sponsor

Lead sponsor
InflaRx GmbHIndustry
Sponsor type
Industry
First posted
Mar 29, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with polyangiitis (GPA) or microscopic polyangiitis (MPA).

Conditions

  • Granulomatosis With Polyangiitis (GPA)
  • Microscopic Polyangiitis (MPA)

Interventions

  • IFX-1Drug

    intravenously administered

  • Placebo-IFX-1Drug

    intravenously administered

  • Glucocorticoid (GC)Drug

    orally administered

  • Placebo-Glucocorticoid (Placebo-GC)Drug

    orally administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Clinical ResponseTime frame: Baseline, Week 16

Locations

76 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Leuven, Belgium

  • Clinical Site

    Liège, Belgium

  • Clinical Site

    Hradec Králové, Czechia

  • Clinical Site

    Prague, Czechia

  • Clinical Site

    Prague, Czechia

  • Clinical Site

    Prague, Czechia

  • Clinical Site

    Angers, France

  • Clinical Site

    Brest, France

  • Clinical Site

    Créteil, France

  • Clinical Site

    Grenoble, France

  • Clinical Site

    Lille, France

  • Clinical Site

    Montpellier, France

  • Clinical Site

    Paris, France

  • Clinical Site

    Paris, France

  • Clinical Site

    Paris, France

  • Clinical Site

    Pessac, France

  • Clinical Site

    Poitiers, France

  • Clinical Site

    Aachen, Germany

  • Clinical Site

    Berlin, Germany

  • Clinical Site

    Cologne, Germany

  • Clinical Site

    Dresden, Germany

  • Clinical Site

    Essen, Germany

  • Clinical Site

    Freiburg im Breisgau, Germany

  • Clinical Site

    Hanover, Germany

  • Clinical Site

    Kirchheim unter Teck, Germany

  • Clinical Site

    Leipzig, Germany

  • Clinical Site

    Ludwigshafen, Germany

  • Clinical Site

    Mannheim, Germany

  • Clinical Site

    Münster, Germany

  • Clinical Site

    Stuttgart, Germany

  • Clinical Site

    Jena, Thuringia, Germany

  • Clinical Site

    Catania, Italy

  • Clinical Site

    Lecco, Italy

  • Clinical Site

    Messina, Italy

  • Clinical Site

    Milan, Italy

  • Clinical Site

    Milan, Italy

  • Clinical Site

    Monza, Italy

  • Clinical Site

    Pavia, Italy

  • Clinical Site

    Pisa, Italy

  • Clinical Site

    Verona, Italy

Showing 40 of 76 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.